The discussion extendsto the importance for tumor-selective AMPK targeting, limitationsof cancer models for AMPK modulator evaluation, and the selectionof combination therapies, all factors for consideration in futureAMPK modulator development for anticancer treatment. The gene discussed is PRKAA2; the disease is cancer.